ProQR Therapeutics NV (PRQR): Fair Value Consensus

ProQR Therapeutics N.V. (PRQR) is a US and Netherlands-based biotech developer creating RNA-based therapies. This price chart demonstrates the asset's dynamics, with its metric fixed at 8.46. The business relies on alliances with industry behemoths, which minimizes risks through a broad research portfolio. Meanwhile, the licensing platform serves as a cash generator, ensuring high liquidity for the company.

For ProQR Therapeutics N.V. (PRQR), a leader in RNA editing, this indicator synthesizes average market expectations for the asset's fair value, reflecting the balance between supply and demand. By analyzing the trajectory of analysts' price targets, investors can observe a cycle of revaluations that, for this biotech firm, depends directly on the success of the Axiomer platform and the partnership with Eli Lilly, confirming the fundamental resilience of the business.